Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study

P B Jeppesen, M Pertkiewicz, A Forbes, L Pironi, S M Gabe, F Joly, B Messing, S Loth, N N Youssef, H Heinze, P Berghöfer

Research output: Contribution to journalArticlepeer-review

78 Citations (Scopus)


Short bowel syndrome (SBS)-intestinal failure (IF) patients have impaired quality of life (QoL) and suffer from the burden of malabsorption and parenteral support (PS). A phase III study demonstrated that treatment with teduglutide, a glucagon-like peptide 2 analogue, reduces PS volumes by 32% while maintaining oral fluid intake constant; placebo-treated patients had reduced PS by 21%, but oral fluid intake increased accordingly. As effects of teduglutide on QoL are unknown, they were investigated here.
Original languageEnglish
Pages (from-to)713-721
Number of pages9
JournalClinical Nutrition
Issue number5
Publication statusPublished - Oct 2013


  • Adult
  • Aged
  • Cost of Illness
  • Double-Blind Method
  • Drinking
  • Drug Resistance
  • Gastrointestinal Agents
  • Glucagon-Like Peptide 2
  • Humans
  • Injections, Subcutaneous
  • Intestinal Diseases
  • Intestine, Small
  • Middle Aged
  • Organ Dysfunction Scores
  • Organ Size
  • Parenteral Nutrition, Home
  • Peptides
  • Quality of Life
  • Receptors, Glucagon
  • Short Bowel Syndrome

Cite this